We are live on !
Find out more
SR One Capital Management Portfolio holdings
AUM
$1.04B
Turnover
29.41%
1-Year Est. Return
262.99%
This Fund
S&P 500
This Quarter Est. Return
+38.77%
1 Year Est. Return
+262.99%
3 Year Est. Return
+655.88%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.04B
AUM Growth
+$124M
(+13%)
Cap. Flow
-$102M
Cap. Flow % of AUM
Cap. Flow %
-9.81%
Top 10 Holdings %
Top 10 Hldgs %
95.11%
Holding
17
New
3
Increased
1
Reduced
–
Closed
2
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.9
years
Top 20 Avg Time Held
1.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Avalyn Pharma
AVLN
|
+$95.5M |
| 2 |
Odyssey Therapeutics
ODTX
|
+$66.5M |
| 3 |
Mobia Medical
MOBI
|
+$25.7M |
| 4 |
Oric Pharmaceuticals
ORIC
|
+$911K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arcellx
ACLX
|
+$269M |
| 2 |
Oruka Therapeutics
ORKA
|
+$21.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Veradermics Inc
MANE
$6.13B
| $295M | 28.42% |
2,401,868
| – | – |
2026 Q1
1 quarter
|
|
2
Zenas BioPharma
ZBIO
$1.96B
| $128M | 12.31% |
5,037,854
| – | – |
2024 Q3
7 quarters
|
|
3
CRISPR Therapeutics
CRSP
$4.52B
| $111M | 10.7% |
2,038,763
| – | – |
2024 Q1
9 quarters
|
|
|
4
Avalyn Pharma
AVLN
$1.36B
| $109M | 10.48% |
+3,308,649
| New | +$95.5M |
2026 Q2
0 quarters
|
|
5
Design Therapeutics
DSGN
$679M
| $94.4M | 9.09% |
6,526,476
| – | – |
2021 Q4
18 quarters
|
|
|
6
Odyssey Therapeutics
ODTX
$934M
| $71M | 6.83% |
+3,794,883
| New | +$66.5M |
2026 Q2
0 quarters
|
|
7
Alumis Inc
ALMS
$827M
| $55.2M | 5.31% |
1,959,896
| – | – |
2024 Q2
8 quarters
|
|
|
8
Oric Pharmaceuticals
ORIC
$944M
| $50M | 4.81% |
4,615,384
+100,455
| +2% | +$911K |
2025 Q2
4 quarters
|
|
9
Mineralys Therapeutics
MLYS
$1.37B
| $42.2M | 4.06% |
1,563,966
| – | – |
2023 Q1
13 quarters
|
|
10
ARS Pharmaceuticals
SPRY
$344M
| $32.1M | 3.09% |
4,012,903
| – | – |
2022 Q4
14 quarters
|
|
|
11
Mobia Medical
MOBI
$402M
| $26.6M | 2.56% |
+1,986,072
| New | +$25.7M |
2026 Q2
0 quarters
|
|
12
Nkarta
NKTX
$104M
| $9.43M | 0.91% |
3,333,333
| – | – |
2022 Q2
16 quarters
|
|
13
Oculis Holding
OCS
$432M
| $8.89M | 0.86% |
641,022
| – | – |
2025 Q1
5 quarters
|
|
14
Ultragenyx Pharmaceutical
RARE
$1.61B
| $4.6M | 0.44% |
137,753
| – | – |
2025 Q4
2 quarters
|
|
15
enGene Therapeutics
ENGN
$117M
| $1.29M | 0.12% |
747,750
| – | – |
2024 Q2
8 quarters
|
|
|
16
DELISTED
Arcellx
ACLX
| – | – |
-2,346,630
| Closed | -$269M | – |
|
|
17
Oruka Therapeutics
ORKA
$6.95B
| – | – |
-430,330
| Closed | -$21.1M | – |
|
Similar funds
SR One Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, SR One Capital Management held 17 positions worth $1.04B, up 13% from $915M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
SR One Capital Management withdrew a net $102M in Q2 2026, closing 2 positions. Its most notable exit was Arcellx, an estimated $269M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, SR One Capital Management opened a new position in Avalyn Pharma worth $109M.
- SR One Capital Management's largest Q2 2026 buy was Avalyn Pharma: 3,308,649 shares worth $109M.
- SR One Capital Management added most to Oric Pharmaceuticals in Q2 2026, an estimated $911K increase.
- SR One Capital Management fully exited Arcellx in Q2 2026, selling an estimated $269M.
- SR One Capital Management's ten largest holdings make up 95% of its $1.04B portfolio in Q2 2026.
- SR One Capital Management opened 3 new positions and closed 2 in Q2 2026.
- SR One Capital Management's portfolio value rose 13% quarter-over-quarter to $1.04B.
Based on SR One Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.